Cargando…
Opposing effects of acute versus chronic inhibition of p53 on decitabine’s efficacy in myeloid neoplasms
Decitabine is a DNA methyltransferase inhibitor and is considered a promising drug to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with p53 mutations. However, whether loss of p53 in fact increases the response of MDS/AML cells to decitabine remains unclear. In this study,...
Autores principales: | Tamura, Moe, Yonezawa, Taishi, Liu, Xiaoxiao, Asada, Shuhei, Hayashi, Yasutaka, Fukuyama, Tomofusa, Tanaka, Yosuke, Kitamura, Toshio, Goyama, Susumu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547685/ https://www.ncbi.nlm.nih.gov/pubmed/31160638 http://dx.doi.org/10.1038/s41598-019-44496-6 |
Ejemplares similares
-
Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia
por: Hayashi, Yasutaka, et al.
Publicado: (2019) -
Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
por: Asada, Shuhei, et al.
Publicado: (2018) -
P407: MITOTIC FIDELITY IS A RESISTANCE MECHANISM TO DECITABINE IN MYELOID TUMORS.
por: Yabushita, Tomohiro, et al.
Publicado: (2023) -
CHIP‐associated mutant ASXL1 in blood cells promotes solid tumor progression
por: Liu, Xiaoxiao, et al.
Publicado: (2022) -
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
por: Tanaka, Yosuke, et al.
Publicado: (2022)